Loading
A phase 3 trial of 9MW2821 in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.
A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer is a phase 3 interventional study registered as NCT06196736 by Mabwell (Shanghai) Bioscience Co., Ltd., with 432 participants planned, started 2023-12-29 and due to reach its primary completion in 2026-09. Interventions recorded: 9MW2821 and Chemotherapy.
Shares Mabwell (Shanghai) Bioscience, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.